bortezomib,carfilzomib,dexamethasone,elotuzumab,cc-92480,daratumumab,isatuximab
takeda,bms,janssen,sanofi,amgen
nct03989414: phase 1/2 - a study of cc-92480 with standard treatments in relapsed &amp; new mm - mm-002 #mmsm #multiplemyeloma #ims2022 
Multiple Myeloma Education Platform for Myeloma Community